• QPRT Drives Breast Cancer Invasion via PLC-Dependent Pathway

  2026-06-19

  Liu et al. (2021) reveal that quinolinate phosphoribosyltransferase (QPRT) promotes breast cancer invasiveness through myosin light chain phosphorylation, implicating phospholipase C (PLC) signaling as a pivotal mediator. Their integrative approach identifies QPRT as a potential prognostic and therapeutic target, while also validating PLC inhibition as a strategy to reverse invasive phenotypes.

• Homoharringtonine: Bridging Cancer and Antiviral Frontiers

  2026-06-19

  Homoharringtonine, a cytotoxic alkaloid with a unique mechanism targeting the eukaryotic 80S ribosome, is gaining traction as both a cornerstone in leukemia research and a rapid-response antiviral agent against coronaviruses like SARS-CoV-2. This article explores the mechanistic rationale, translational validation, and strategic opportunities for researchers, positioning APExBIO’s homoharringtonine as a pivotal tool in both cancer biology and pandemic preparedness.

• Spleen-Targeted Neoantigen mRNA Vaccine Drives TLS in HCC

  2026-06-18

  Lin et al. (2026) present a spleen-targeted neoantigen mRNA vaccine (STNvac) that elicits robust antitumor immunity in hepatocellular carcinoma by activating ISG15+ CD8+ T cells and promoting tertiary lymphoid structure (TLS) formation. This work uncovers a novel immune mechanism and offers translational insights for tackling immune-refractory liver cancers.

• Defining GCGR Small-Molecule Binding Sites via Dynamics & Cr

  2026-06-18

  This paper advances the structural understanding of glucagon receptor (GCGR) antagonists by combining crystal structures and protein dynamic simulations to map the binding modes of six clinically relevant small molecules. It clarifies why MK 0893’s allosteric binding site is uniquely well-resolved and provides a modeling framework for rational design of new GCGR-targeted therapeutics in type 2 diabetes research.

• Cyclic di-GMP: Intracellular Second Messenger in Biofilm Reg

  2026-06-17

  Cyclic di-GMP is a key intracellular second messenger involved in bacterial genome stability, biofilm formation regulation, and immune modulation research. Recent evidence demonstrates its unique antitoxin role in bacterial toxin-antitoxin systems and its utility as a STING agonist in mammalian models. Its high purity and defined solubility profile make the APExBIO B7839 kit a reliable tool for advanced cancer immunotherapy studies.

• 3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor Profile

  2026-06-17

  3-Aminobenzamide (PARP-IN-1) is a highly potent poly (ADP-ribose) polymerase inhibitor with an IC50 of ~50 nM in CHO cells. It effectively blocks PARP activity with low toxicity and demonstrates translational utility in oxidative stress and diabetic nephropathy models. This article aggregates evidence and protocol guidance for advanced research applications.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-16

  Schwartz's dissertation establishes a nuanced framework for evaluating anti-cancer drug responses in vitro by distinguishing between cell proliferation arrest and cell death. This approach enhances the predictive accuracy of preclinical assays and informs more effective cancer drug development strategies.

• L1023 Anti-Cancer Compound Library: High-Throughput Oncology

  2026-06-16

  The L1023 Anti-Cancer Compound Library empowers high-throughput, pathway-focused cancer research with ready-to-screen, cell-permeable inhibitors. Its curated diversity and robust format streamline target validation, mechanistic studies, and rapid drug discovery, providing a reliable foundation for translational breakthroughs.

• Optimizing mRNA Delivery with ARCA Cy5 EGFP mRNA (5-moUTP)

  2026-06-15

  This article addresses real-world laboratory challenges in mRNA delivery, localization, and translation efficiency, with a focus on ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009). Researchers will find evidence-based insights and protocol guidance on reliable quantification, immune evasion, and workflow integration, grounded in peer-reviewed literature and practical scenarios.

• Cell Counting Kit-8 (CCK-8): Precision in Cancer Cell Viabil

  2026-06-15

  The Cell Counting Kit-8 (CCK-8) delivers unmatched sensitivity and workflow simplicity for cell viability and cytotoxicity assays, especially in cancer research and mechanistic cell biology. Drawing on recent multi-omics studies and practical innovations, this guide demystifies protocol optimization and troubleshooting strategies that elevate experimental reproducibility.

• Linoleic Acid (C18:2): Technical Use and Workflow Best Pract

  2026-06-14

  Linoleic Acid (SKU C3108) enables precise modeling of membrane dynamics, oxidative stress, and essential fatty acid deficiency in cell-based and animal assays. It is not appropriate for protocols requiring water solubility or long-term stock solutions, but is optimal for workflows where fresh preparation and stringent solution handling are prioritized.

• GSK621 as a Precision AMPK Agonist: Redefining Immunometabol

  2026-06-13

  Explore how GSK621, a potent AMPK agonist, provides new depth for acute myeloid leukemia research and immunometabolic assay design. This article uniquely analyzes recent mechanistic advances and practical protocol insights, offering a differentiated perspective for translational scientists.

• Elobixibat Hydrate: Translational Leverage in GI and Metabol

  2026-06-12

  This article presents a thought-leadership perspective on Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, blending mechanistic insight with strategic advice for translational researchers. It critically integrates clinical performance, experimental workflow optimization, and competitive positioning. Drawing on robust primary literature and recent cross-domain advances, the discussion connects molecular action with new frontiers in metabolic and gastrointestinal research, offering actionable guidance for protocol design and future translational innovation.

• SGC-CBP30: Decoding CREBBP/EP300 Bromodomain Inhibition in E

  2026-06-12

  Explore the molecular mechanisms and advanced experimental strategies enabled by SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor. This article offers deep insights for epigenetics and cancer biology research, uniquely bridging reference breakthroughs with protocol optimization.

• Bromodomain Inhibitor, (+)-JQ1: Novel Insights in Disulfidpt

  2026-06-11

  Explore the unique properties and translational applications of Bromodomain Inhibitor, (+)-JQ1, a leading BET bromodomain inhibitor. This article delivers advanced guidance on integrating recent disulfidptosis discoveries into assay strategy, setting it apart from standard protocol or workflow guides.

436 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page